Pentylenetetrazole - Balance Therapeutics

Drug Profile

Pentylenetetrazole - Balance Therapeutics

Alternative Names: BTD-001

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Balance Therapeutics
  • Class Antihypotensives; Azepines; Nootropics; Respiratory stimulants; Sleep disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Central nervous system stimulants; GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypersomnia; Narcolepsy
  • Phase I Down syndrome

Most Recent Events

  • 03 May 2017 Phase-I clinical trials in Down syndrome (In volunteers) in United Kingdom (PO) (NCT03150498)
  • 03 May 2017 Balance Therapeutics initiates enrolment in a phase I trial in healthy volunteers in United Kingdom (NCT03150498)
  • 04 Apr 2017 Balance Therapeutics plans a phase I trial in healthy male volunteers in USA (NCT03107013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top